Ivosidenib

Ivosidenib (Tibsovo) is a prescription medication used to treat acute myeloid leukemia (AML) that has a certain genetic change. It is a type of targeted therapy called a kinase inhibitor. Ivosidenib works by blocking the activity of a certain protein called an IDH1 enzyme, which is involved in abnormal cell growth in AML. Ivosidenib is taken orally in tablet form. Common side effects include nausea, fatigue, diarrhea, vomiting, and increased levels of liver enzymes.

Ivosidenib, sold under the brand name Tibsovo, is a relatively new prescription medication classified as a targeted therapy used to treat a specific type of cancer. Here's a breakdown of its key aspects:

Function:

• FL3-ITD Mutation Inhibitor: Ivosidenib targets a specific genetic mutation (FLT3-ITD) found in some types of acute myeloid leukemia (AML), a cancer of the blood and bone marrow. This mutation can cause abnormal cell growth.
• Mechanism: Ivosidenib works by inhibiting the FLT3 protein, which plays a crucial role in the growth and survival of leukemia cells harboring the FLT3-ITD mutation. By blocking this protein, Ivosidenib helps control the growth and spread of cancerous cells.

Applications:

• Acute Myeloid Leukemia (AML): Ivosidenib is approved for the treatment of adults with relapsed or refractory (resistant to standard treatment) AML who have the FLT3-ITD mutation.

Important Considerations:

• Genetic Testing Required: A doctor will perform a genetic test to confirm the presence of the specific FLT3-ITD mutation before recommending Ivosidenib.
• Prescription Medication: Ivosidenib is a powerful medication that requires a doctor's prescription and close monitoring throughout therapy.
• Combination Therapy: Ivosidenib may be used alone or in combination with other chemotherapy drugs depending on the individual's specific case.
• Potential Side Effects: Like any medication, Ivosidenib can cause side effects, including:
  • Fatigue
  • Nausea
  • Diarrhea
  • Vomiting
  • QT prolongation (a heart rhythm abnormality)